The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
GPRC5D as a novel immunotherapeutic target in multiple myeloma
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GPRC5D (G protein-coupled receptor, class C, group 5, member D) is a G-protein-coupled orphan receptor that highly expressed in malignant bone marrow plasma cells from CD138+ MM patients. Its expression in normal tissues is primarily limited to the hair follicle region. Importantly, GPRC5D is expressed independently of BCMA, making it a promising target for multiple myeloma therapy [214, 215].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [215]
Citations
Cites
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204591 · Cited by 744
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
Smith, E. L., Harrington, K., Staehr, M., Masakayan, R., Jones, J., Long, T. J., Ng, K. Y., Ghoddusi, M., Purdon, T. J., Wang, X., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau7746 · Cited by 391
Pillarisetti, K., Edavettal, S., Mendonça, M., Li, Y., Tornetta, M., Babich, A., Majewski, N., Husovsky, M., Reeves, D., Walsh, E., et al. (2020) · Blood · doi:10.1182/blood.2019003342 · Cited by 174
Research works printed but not linked: 7
- Mailankody, S. & Landgren, O. T-cell engagers — modern immune-based therapies for multiple myeloma. New Engl. J. Med. 387, 558–561 (2022). · DOI
- Mailankody, S. et al. GPRC5D-targeted CAR T cells for myeloma. New Engl. J. Med. 387, 1196–1206 (2022). · DOI · Paper page
- Bal, S. et al. Clinical activity of BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed and/or refractory (R/R) multiple myeloma (MM): first results from a phase 1, multicenter, open-label study. Blood 140, 883–885 (2022). · DOI · Paper page
- Huang, H. et al. Phase I open-label single arm study of GPRC5D CAR T-cells (OriCAR-017) in patients with relapsed/refractory multiple myeloma (POLARIS). J. Clin. Oncol. 40, 8004–8004 (2022). · DOI
- Carlo-Stella, C. et al. RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study. Blood 140, 397–399 (2022). · DOI
- Falchi, L., Vardhana, S. A. & Salles, G. A. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns and opportunities. Blood https://doi.org/10.1182/blood.2021011994 (2022). · DOI
- Fernández de Larrea, C. et al. Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma. Blood Cancer Discov. 1, 146–154 (2020). · DOI · Paper page
Cited by
Sorted by citations
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90
Metadata
- Authors
- Nath, K., Costa, B. A., & Mailankody, S.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Mailankody, Sham
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2023-02-01
- Volume
- 20
- Issue
- 5
- Pages
- 281-282
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W4318767939
- Cited by
- 27
- References
- 3
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 14 · 2023: 8
- FWCI
- 5.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- GPRC5D, multiple myeloma, immunotherapy targets, chimeric antigen receptor T cells, bispecific antibodies, relapsed/refractory multiple myeloma, immune checkpoint
- MeSH terms
- Humans, Immunotherapy, Multiple Myeloma, Receptors, G-Protein-Coupled
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
